CDK4

This international study aimed to identify genetic prognostic biomarkers in a specific subgroup of intermediate-risk neuroblastoma patients, over 18 months old, without MYCN amplification, with localized unresectable or stage 3 tumors, and unfavorable histology, who experience poorer outcomes. Researchers analyzed chromosomal copy number alterations, next-generation DNA sequencing, telomere maintenance mechanisms, and gene expression. The findings revealed that oncogene amplifications, p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent prognostic markers associated with significantly reduced event-free and overall survival. These discoveries suggest that these patients might benefit from intensified or alternative treatments.

Somatic mutations in GC-rich promoter regions are significant drivers of cancer, yet their detection is challenging due to poor sequencing coverage in these areas. This study introduces a hybrid capture assay optimized for over 3000 cancer gene promoters, enabling deep sequencing of these complex regions. This method facilitates the discovery of reliable point mutations, short insertions/deletions, copy number variants, and mutational signatures. The assay nominated candidate noncoding driver mutations in CDK4, SMAD3, and GATA3 in breast cancer, paving the way for future functional follow-up.

Improved survival rates for reproductive-age breast cancer patients highlight significant oncofertility challenges. Fertility preservation, gonadotoxicity, and pregnancy safety are key concerns requiring early and integrated management within the therapeutic plan. Prompt referral for fertility preservation is crucial, ensuring it does not compromise oncologic outcomes. Modern therapies such as PARP inhibitors, CDK4/6 inhibitors, HER2-monoclonal antibodies, and endocrine treatments raise specific questions due to a lack of prospective human fertility data. A precautionary approach is recommended, including effective contraception and adherence to washout periods.

The treatment paradigm for hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) has significantly evolved from sequential therapies to more personalized strategies. CDK4/6 inhibitors combined with endocrine therapy remain the first-line standard of care, consistently improving progression-free survival and, for some agents, overall survival. The emergence of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan is reshaping the therapeutic landscape, including for HER2-low and HER2-ultralow disease. Metastasis-directed therapy is also considered for oligometastatic or oligoprogressive disease, requiring nuanced decision-making. Overall management now integrates tumor biology, therapeutic advances, and patient-defined goals of care.